Needham Initiates Coverage On Haemonetics with Buy Rating, Announces $138 Price Target

Needham analyst Mike Matson initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and a $138 price target.

Benzinga · 01/10/2020 12:38

Needham analyst Mike Matson initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and a $138 price target.